PMS Public API – Terms and Conditions

12 June 2026

By registering with the European Medicines Agency's (EMA) Application Programming Interface (API) for the use of EMA's public version of its Product Management Service (PMS) platform, I accept the following:

- I have read, understood and agreed to comply with the **EMA's API General Terms and Conditions of Use (Terms of Use)**, including any updates thereto. EMA may terminate or suspend access to any part or feature of the API without prior notice in case of failure to comply with the Terms of Use or any other relevant guidelines and rules as published by EMA.

- I understand that the data and information on medicinal products made available through the PMS platform are compiled from **multiple data sources** and may have undergone **various processing and transformation steps** prior to being made available to users. Depending on the medicinal product and the individual data element concerned, this information may originate from one or more of the following EU Network sources:

    - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD), containing information on both centrally authorised products (CAPs) and nationally authorised products (non-CAPs) provided by Marketing Authorisation Holders;
    - SIAMED, the EMA managed database containing information related to centrally authorised products (CAPs); and/or
    - Data submissions provided directly to PMS by relevant stakeholders in accordance with applicable regulatory processes.

- I understand that, as part of the integration of these various data sources into PMS, certain data elements may have been subject to **technical processing, transformation, harmonisation, or mapping** to ensure their usability and consistency within the system. Information on the origin of specific data elements, the applicable product scope, and the transformations applied during the integration process is provided in the European Union Implementation Guide (EU IG), in Chapters 3, 7, and 9. Pursuant to Annex A of Chapter 5 of the EU IG, the information on medicinal products undergoes additional processing to ensure that any confidential data is removed.

- I understand that Medicinal product information in PMS/API is for **reference only**, not formally validated by National Competent Authorities, and may differ from national records. In case of discrepancies, the relevant authority's records prevail.

- I acknowledge that the public PMS API is currently made available as part of a **beta release**. During the beta release:

    - I can explore the structure, content, and potential uses of medicinal product data available through the public PMS API. The API may be used for familiarisation, testing, and analytical exploration but **should not be used for business purposes.** The transition to full public release will be announced via official EMA channels.
    - the functionality, scope, structure, and content of the public PMS API **may evolve**. EMA reserves the right to modify, expand, restrict, or otherwise adjust the API, the datasets made available, and the related technical specifications at any time during this period.

- I acknowledge that in the future, after transition to production, the API shall only be used with **EMA's prior authorisation** to sell, sublicence, incorporate or redistribute its content (or any portion of it).

- I acknowledge that EMA provides APIs to enhance public access to information on medicines. If **erroneous or incomplete or inaccurate data** or information are brought to EMA's attention via a ticket raised through EMA ServiceNow, EMA will evaluate the request and take appropriate measures, where applicable. However, EMA accepts no responsibility or liability whatsoever (including, but not limited to, any direct or consequential loss or damage that might occur to you and/or any other third party) arising out of, or in connection with, the use of EMA's API.